Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Annette Hudler

Internal Medicine Purcellville, VA Doctor of Osteopathy

NPI 1487699161 CMS profile 113136

205 E. Hirst Road, Suite 203, Purcellville, VA 20132

Open in the dashboard

General payments

$7,395

428 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annette Hudler of Purcellville, VA is reported in the CMS Open Payments database as having received $7,395 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $62 3
2024 General $1,576 80
2023 General $1,528 78
2022 General $1,197 68
2021 General $1,079 74
2020 General $796 46
2019 General $1,157 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annette Hudler
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Annette Hudler were reported at $62. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Annette Hudler Internal Medicine median Middle half National median
2019 $1,157 $159 $48–$570 $163
2020 $796 $119 $33–$402 $114
2021 $1,079 $135 $37–$521 $132
2022 $1,197 $141 $42–$496 $149
2023 $1,528 $149 $45–$519 $160
2024 $1,576 $154 $47–$537 $164
2025 $62 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,447 93 payments
  2. AstraZeneca Pharmaceuticals LP $1,406 71 payments
  3. AbbVie, Inc. $802 51 payments
  4. Pfizer Inc. $517 29 payments
  5. Lilly USA, LLC $434 23 payments
  6. GlaxoSmithKline, LLC. $296 17 payments
  7. Sanofi-Aventis U.S. LLC $252 15 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $214 20 payments
  9. Astellas Pharma US Inc $208 6 payments
  10. Merck Sharp & Dohme Corporation $189 12 payments
  11. Other $1,631 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,234 424 payments
  2. Education $161 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $924 62 payments
  2. FARXIGA $919 44 payments
  3. RYBELSUS $811 53 payments
  4. Wegovy $323 17 payments
  5. VRAYLAR $321 24 payments
  6. NURTEC ODT $280 16 payments
  7. TRELEGY ELLIPTA $261 15 payments
  8. QULIPTA $250 11 payments
  9. BREZTRI $247 13 payments
  10. ELIQUIS $175 11 payments
  11. Other $5,686 328 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,674

Median for Internal Medicine: 777

Drug cost

$588,098

Median for Internal Medicine: $73,373

Branded share of claims

19%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 58 $92,475
Eliquis Apixaban Brand 86 $85,043
Farxiga Dapagliflozin Propanediol Brand 53 $63,307
Jardiance Empagliflozin Brand 35 $41,420
Mounjaro Tirzepatide Brand 30 $38,285
Trulicity Dulaglutide Brand 19 $26,219
Rybelsus Semaglutide Brand 13 $22,522
Tresiba Flextouch U-100 Insulin Degludec Brand 26 $22,170
Januvia Sitagliptin Phosphate Brand 14 $19,932
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $18,576

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$134,062

Of which drugs: $20,220

Medicare patients

431

Average age 75

Services billed

1,797

294 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 46%
Diabetes 19%
Ischemic heart disease 17%
Cancer 17%
Atrial fibrillation 16%
Chronic kidney disease 13%
Osteoporosis 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 52 52 $15,004
Vaccine for influenza for injection into muscle 90662 Office 60 60 $4,870

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $161
$161 53 —
Wegovy
  • Novo Nordisk Inc $155
$155 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $141
$141 — —
VRAYLAR
  • AbbVie, Inc. $132
$132 — —
RYBELSUS
  • Novo Nordisk Inc $123
$123 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record